Finerenone(Kerendia)

A prescription drug targeting the mineralocorticoid receptor, approved by the FDA in the United States on July 9, 2021. Use only as directed by a doctor.

Lucius-related Certificates

Drug Testing Report

Drug Approval Certificate

Target of Action

Mineralocorticoid receptor

Dosage and Administration

Finerenone route and frequency: oral, once daily.

The dose of finerenone should be adjusted according to the patient's actual condition. Consult a physician and follow medical advice.

Recommended reading: Finerenone Dosage and Administration

Side Effects

Common side effects: chronic kidney disease associated with type 2 diabetes, HFLVEF ≥40%.

Serious side effects: hyperkalemia, worsening renal function in heart failure patients.

Reference article: Side Effects of Finerenone

Use in Special Populations

Breastfeeding: Avoid breastfeeding during treatment and for one day after treatment.

Daily Precautions

1. Advise patients to regularly monitor serum potassium levels. Recommend that patients consult a clinician before using potassium supplements or salt substitutes containing potassium.

2. Advise patients to avoid using strong or moderate CYP3A4 inducers and to choose alternative drugs with no or weak CYP3A4 induction.

3. Advise patients to avoid consuming grapefruit or drinking grapefruit juice at the same time, as it may increase the blood concentration of finerenone.

来自FDA，2022.09